Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody
Open Access
Abstract
Antibody-dependent cellular cytotoxicity (ADCC) is a major mechanism by which antitumor antibodies mediate therapeutic efficacy. At present, we evaluate an Fc-optimized (amino acid substitutions S239D/I332E) FLT3 antibody termed 4G8-SDIEM (FLYSYN) in patients with acute myeloid leukemia (NCT02789254). Here we studied the possibility to induce NK cell ADCC against B-cell acute lymphoblastic leukemia (B-ALL) by Fc-optimized FLT3 antibody treatment. Flow cytometric analysis confirmed that FLT3 is widely expressed on B-ALL cell lines and leukemic cells of B-ALL patients. FLT3 expression did not correlate with that of CD20, which is targeted by Rituximab, a therapeutic monoclonal antibody (mAb) employed in B-ALL treatment regimens. Our FLT3 mAb with enhanced affinity to the Fc receptor CD16a termed 4G8-SDIE potently induced NK cell reactivity against FLT3-transfectants, the B-ALL cell line SEM and primary leukemic cells of adult B-ALL patients in a target-antigen dependent manner as revealed by analyses of NK cell activation and degranulation. This was mirrored by potent 4G8-SDIE mediated NK cell ADCC in experiments with FLT3-transfectants, the cell line SEM and primary cells as target cells. Taken together, the findings presented in this study provide evidence that 4G8-SDIE may be a promising agent for the treatment of B-ALL, particularly in CD20-negative cases.Keywords
Funding Information
- Wilhelm Sander-Stiftung (2007.115.3)
- Deutsche Krebshilfe (70112914, 70113496)
- Deutsche Forschungsgemeinschaft (39090067)
This publication has 46 references indexed in Scilit:
- Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity in Tumor Immunotherapy with Therapeutic AntibodiesFrontiers in Immunology, 2013
- Treatment of HER2-positive breast cancer: current status and future perspectivesNature Reviews Clinical Oncology, 2011
- Isolation of human mAbs that directly modulate FMS‐related tyrosine kinase 3 signalingCancer Science, 2011
- Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 casesLeukemia & Lymphoma, 2011
- Clinical relevance of FLT3 receptor protein expression in Indian patients with acute leukemiaAsia-Pacific Journal of Clinical Oncology, 2010
- RituximabDrugs, 2010
- Rituximab: Mechanism of ActionSeminars in Hematology, 2010
- Functions of natural killer cellsNature Immunology, 2008
- Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemiaBlood, 2007
- Effects of protein aggregates: An immunologic perspectiveThe AAPS Journal, 2006